Published in final edited form as:

Nanomedicine. 2008 March ; 4(1): 1–7.

Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using Atomic Force Microscopy

W. D. Marcus, Ph.D.^{1,2}, H. Wang, Ph.D.¹, S. M. Lindsay, Ph.D.^{1,3}, and M. R. Sierks, Ph.D.²

¹Department of Physics and Astronomy, Arizona State University, Tempe, AZ 85287

²Department of Chemical and Materials Engineering, Arizona State University, Tempe, AZ 85287

³The Biodesign Institute at Arizona State University, Arizona State University, Tempe, AZ 85287

Abstract

Fibrillar amyloid is the hallmark feature of many protein aggregation diseases, such as Alzheimer's and Parkinson's Diseases. A monoclonal single chain variable fragment (scFv) targeting insulin fibrils was isolated using phage display technology and an atomic force microscopy (AFM) mica substrate. Specific targeting of the scFv to insulin fibrils but not monomers or other small oligomeric forms, under similar conditions, was demonstrated both by Enzyme linked immunosorbent assays (ELISA's) and AFM recognition imaging. The scFv also recognizes beta-amyloid fibrils, a hallmark feature of Alzheimer's disease. The results suggest that the isolated scFv possibly targets a shared fibrillar motif - likely the cross-beta sheet characteristic of amyloid fibrils. The techniques outlined here provide additional tools to further study the process of fibril formation. The scFvs isolated can have potential use as diagnostic or therapeutic reagents for protein aggregation diseases.

Keywords

Amyloid fibrils; scFv; AFM; phage display; cross-beta sheet

BACKGROUND

There are approximately 20 known diseases (such as Alzheimer's Disease, Parkinson's Disease and Type II Diabetes), characterized by the aggregation of benign, physiological monomeric peptides/proteins into toxic oligomeric and/or fibrillar aggregates [1]. There is evidence that both oligomeric [2,3] and fibrillar [4] aggregates cause the characteristic cytotoxicity leading to some of these diseases. Therefore, there is considerable interest in understanding these aggregates and developing sensitive diagnostics and therapeutics that can target them for removal, either proteolytically or immunologically.

Insulin is a polypeptide hormone that regulates the metabolism of carbohydrates. A significant reduction in (or resistance to) the amount of insulin that the body produces is a hallmark of Type II Diabetes. The structure of insulin consists of two polypeptide chains (chain A consists of 21 amino acids, chain B has 30) linked by two disulfide bridges. The ability of insulin to

Corresponding author: Warren D. Marcus, wdmarcus@alum.mit.edu (No longer at ASU, but all work performed while there), Altor Bioscience Corporation, 2810 N Commerce Parkway, Miramar, FL 33025, (954) 443 8600 Ext. 844, (954) 443 8610 (Fax).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

readily aggregate into amyloid fibrils at acidic pH [5], as well as its affordability relative to other amyloidogenic proteins/peptides, made it an ideal target for this work.

Antibody phage display is a powerful technique for isolating antibodies against protein antigens [6]. Here, a synthetic antibody phage display library was used to isolate monoclonal single chain variable fragments (scFvs) targeting insulin fibrils utilizing mica, an atomic force microscopy (AFM) substrate, during the biopanning process. AFM recognition imaging [7,8] was used to verify specific binding of the scFv to the fibrillar form of insulin. The scFv also bound fibrillar beta-amyloid, a protein correlated with Alzheimer's Disease [9]. While antibodies have been previously isolated against amyloid fibrils using conventional immunization protocols [10], the scFv's isolated here by phage display techniques provide several significant advantages including: 1) they can be readily affinity matured to yield scFvs with high affinity and specificity [11]; 2) bispecific scFv's or diabodies [12] can be constructed that can modify, label or clear the targeted amyloid fibrils; and 3) the scFv's can be expressed intracellularly as intrabodies [13] enabling the targeting of intracellular fibrillar aggregates.

METHODS

Materials

The human single fold scFv libraries I + J (Tomlinson I + J), *Escherichia coli* TG1 and HB2151, and KM13 helper phage were obtained from the Medical Research Council (MRC). Insulin (from bovine pancreas) was obtained from Sigma-Aldrich (St. Louis, MO).

Biopanning

Selection of phage against the fibrillar morphology of insulin was performed by incubating a 10 μ L aliquot of 4×10^{12} pfu/mL of phage obtained from the Tomlinson (I + J) library with a 10 μ L sample of fibrillar insulin for 2 minutes. Presence of fibrillar insulin was verified by AFM. A 10 μ L aliquot of the incubated solution was deposited on freshly cleaved mica and allowed to absorb onto the mica surface for 5 minutes. The sample was subsequently washed 10 times with 1 mL PBS-Tween 0.1% and 15 times with PBS in order to eliminate the non-specifically bound phage. The bound phage were eluted from the mica surface by incubation with triethylamine (7.18 M, pH=11) for 10 minutes, followed by neutralization with 1 M Tris/HCl, pH 7.4 and then hydrolysis with trypsin (1 mg/mL) and calcium chloride (1 mM) for 30 minutes. To determine the number of eluted phage, 1.2 mL of TG1 at OD₆₀₀ = 0.4 was added to 500 μ L of eluted phage and incubated for 30 minutes at 37 °C. The infected *E.coli* cells were plated in serial dilution on agar containing ampicillin (100 μ g/mL) plates. Eluted phage were amplified by infection of fresh *E.coli* TG1 cells in the presence of helper phage KM13 (5×10^{10}) following the protocol provided on the MRC website (<http://www.geneservice.co.uk/products/proteomic/datasheets/tomlinsonIJ.pdf>). The phage were purified from the culture supernatant by polyethylene glycol precipitation and resuspended in PBS before use in the next round of panning as described. We have successfully used this biopanning protocol to isolate scFvs specific to both fibrillar [14] and oligomeric [15] protein morphologies.

Monoclonal Phage/scFv ELISA

ELISA's were performed as described on the MRC website (<http://www.geneservice.co.uk/products/proteomic/datasheets/tomlinsonIJ.pdf>). Briefly, after 3 rounds of panning, individual clones in TG1 were grown in microtiter wells and phage were produced by addition of KM13 helper phage. Antibody-coated phage were then added to corresponding wells of a coated (10 μ g of target protein) plate and detected by an anti-M13 (HRP) antibody (GE Healthcare, Piscataway, NJ). For scFv ELISA's, the periplasmic fraction of induced HB2151 clones were added to the wells instead of phage. The myc-tag site on the

scFv was used for detection by the anti-myc antibody (9E10) and a secondary goat-anti-mouse IgG (HRP) antibody was used to label the anti-myc antibody. Both antibodies are from Santa Cruz Biotech (Santa Cruz, CA).

Preparation of periplasmic fraction

The periplasmic fraction of an induced, overnight culture was prepared by resuspending the bacterial pellet in a 1:20 (v/v) amount of TSE (50 mM Tris, 20% sucrose, 1 mM EDTA, pH 7.5) for 30 minutes at 4°C. This mixture was then spun down for 30 minutes at 10,000 × g and the periplasmic fraction was collected in the supernatant.

Site-directed mutagenesis

Mutagenesis was performed essentially as described [7]. Briefly, primers were designed to change the spurious amber codon (TAG) to CAG (glutamine) at amino acid position H53 (<http://www.geneservice.co.uk/products/proteomic/datasheets/tomlinsonIJ.pdf>) by using the 21 nucleotides flanking the amber codon in the heavy chain: forward (5' TGG GTC TCA GGT ATT GAT CCT CAG GGT CTG AGG ACA GTG TAC GCA 3') and reverse (5' TGC GTA CAC TGT CCT CAG ACC CTG AGG ATC AAT ACC TGA GAC CCA 3'). The following mixture was added to a PCR tube on ice: 33 µL of water, 2 µL of 50 mM MgSO₄, 5 µL of 10x *Pfx* Amplification Buffer, 4 µL dNTP's, 1 µL of each mutagenesis primer, 5 µL of isolated plasmid and 2 µL Platinum *Pfx* Polymerase. The following thermocycler conditions were used: Initial cycle for 60 seconds and 94°C, then 12 cycles of 30 seconds at 94°C, 30 seconds at 55°C and an extension time of 10 minutes at 68°C (extension time is based on 2 min/kbp of plasmid). A 1 µL aliquot of DpnI and 5.7 µL of NEBuffer 4 were added to the PCR mixture and incubated at 37°C for 1 hour. A 200 µL aliquot of chemically competent HB2151 cells were added to the mixture. The mixture was placed on ice for 30 minutes, at 42°C for 3 minutes to heat shock the culture, and then placed in ice for 3 minutes. A 100 µL aliquot of the mixture was plated onto LB agar plates (supplemented with 100 µg/mL of ampicillin) and grown overnight at 37°C.

Dot Blot

A 2 µL aliquot of sample was placed on a nitrocellulose membrane. The membrane was blocked with 2% milk in PBS, pH 7.4 for one hour at room temperature. The membrane was washed once with PBS and then stained with anti-myc-tag mouse antibody (Santa Cruz Biotechnology, USA) at 1:500 dilution in PBS for one hour at room temperature. The membrane was washed 3 times with PBS and then stained with a goat-anti-mouse IgG HRP conjugate antibody at 1:1000 dilution in 2% MPBS for one hour at room temperature. The membrane was then washed 3 times with PBS and developed using DAB substrate (Sigma, USA).

Purification of G5 scFv

A 1L culture of *E. coli* HB2151 containing the G5 (anti-Insulin fibril) scFv phagemid was grown (shaking at 250 rpm at 37°C) in 2xTY and 100 µg/mL ampicillin to OD₆₀₀=0.5. A 1 mL aliquot of 1M IPTG was added to the culture to induce scFv expression. The culture was grown overnight (shaking at 250 rpm) at 30°C. The following day, the culture was spun down at 10,000g for 10 minutes. The pellet was resuspended in 50 mL of the osmotic shock buffer TSE (50 mM Tris, 20% sucrose, 1 mM EDTA, pH 7.5) for 30 minutes at 4°C. The buffer was spun down at 10,000g for 30 minutes. The supernatant was added to the sample loop of the ÄKTA FPLC system (Amersham Pharmacia Biotech, Piscataway, NJ) and the scFv was purified using a HiTrap Protein A (5 mL) column. Glycine (0.2 M, pH 3.0) was used to elute the scFv from the column. After collection of eluted peaks, the pH was immediately neutralized by addition of NaOH. The purified sample was then dialyzed overnight in PBS and purity

checked by SDS gel electrophoresis. The scFv concentration was determined using a BCA protein assay kit (Pierce, Rockford, IL).

Sample preparation

Fibrillar insulin was prepared by dissolving 1 mg of lyophilized insulin into a 1 ml solution of 40 mM HCl for 24 hours at 60°C. Human Swi/Snf, a chromatin-regulating complex, was prepared as described [16]. The hSwi/Snf was deposited on glutaraldehyde aminopropyltriethoxysilane (GD-AP TES)-treated mica, derivatized at 1 μ M levels with GD as described [17], and allowed to adsorb for 40 min. Fibrillar beta-amyloid samples were prepared as described [18]

Atomic Force Microscopy Recognition Imaging

The anti-fibrillar insulin scFv, G5, and the control anti-BRG1 scFv were tethered to silicon nitride cantilevers and used to generate recognition images essentially as described [8]. Briefly, antibodies were thiolated and attached to a polyethylene glycol (PEG) tether on the end of the AFM probe. Amination of the probe was carried out by exposing a UV-cleaned silicone-nitride probe to aminopropyltriethoxysilane vapor for 1 hour. The recognition signal was obtained by PicoTREC (Molecular Imaging, Tempe, AZ). Magnetized cantilevers are driven by a MacMode dynamic-force microscope (Molecular Imaging, Tempe, AZ). Images were taken in 10 mM NaCl/5 mM phosphate buffer, pH 7.5, with 3-nm peak-to-peak amplitude oscillation at 8 kHz, imaging at 70% set point, and scanning at 1 Hz. The recognition and topographical images were obtained simultaneously.

RESULTS

Insulin sample characterizations

The prepared “monomeric” and “fibrillar” insulin samples were characterized by electrophoresis on a 10% acrylamide gel in a tricine buffer. The monomeric sample showed a dominant broad band below 14.2 kD while the fibrillar sample showed only a faint band at a similar size with the bulk of the sample remaining in the loading well (Fig. 1A). A more sensitive silver stain development protocol indicated the broad band seen with the “monomeric” sample contained four bands corresponding to monomer, dimer, trimer and tetramer forms of insulin (data not shown), indicating some oligomerization of the sample immediately after dissolving insulin powder in 40 mM HCl. Fibrillar samples were also verified by AFM imaging.

Isolation of scFv targeting insulin fibrils

After three rounds of biopanning with the Tomlinson (I + J) scFv library against insulin fibrils that were deposited on freshly cleaved mica, individual clones were selected and binding specificity for insulin fibrils determined by monoclonal phage ELISA (data not shown). The clone having the highest ELISA signal, G5, was selected for further characterization.

The DNA sequence of the G5 scFv indicated the presence of a spurious amber stop codon (TAG) at amino acid position H53, one of the randomized residues of the heavy chain. Site-directed mutagenesis was used to correct the gene sequence, changing the amber codon to glutamine (CAG). The corrected gene was then transformed into *E. coli* bacteria HB2151 for induction and soluble secretion of scFv. Soluble secretion of the G5 scFv was verified by dot blot analysis. Binding specificity of the soluble G5 scFv for the different forms of insulin was determined by soluble ELISA using the periplasmic fraction of the induced corrected G5 clone. Similar amounts of fibrillar and monomeric insulin were coated to the ELISA plates (verified by BCA analysis of wells - data not shown). There is significant binding of the G5 scFv to the fibrillar sample when compared to the monomeric sample ($p < 0.005$). However, there was no

significant binding of the monomeric insulin sample when compared to the control well, which contains no insulin (Fig. 1B).

Atomic force microscopy recognition imaging of insulin fibrils

To demonstrate that the scFv binds insulin fibrils, we utilized AFM recognition imaging as previously described [7,8]. Insulin fibrils were deposited on freshly cleaved mica and imaged topographically (Fig. 2A). The G5 scFv was immobilized on the AFM tip and was used for recognition imaging with directional scans going from left to right (Fig. 2B) and right to left (Fig. 2C). The black areas seen on the recognition images represent specific antibody-antigen interactions.

We then tested whether the scFv would recognize non-fibrillar forms of insulin. A fresh sample of insulin dissolved in 40 mM HCl was placed on freshly cleaved mica, and imaged both topographically (Fig. 2D) and with recognition imaging (Figs. 2E/F) utilizing the same AFM tip used in the fibrillar studies above. AFM recognition imaging did not show any interaction between the immobilized scFv and the monomeric, dimeric, trimeric and tetrameric insulin forms (as determined by tricine gel separation of the “monomeric” sample in Fig. 1A and silver staining (not shown)).

Control recognition imaging data

To verify that a control non-fibril specific scFv did not also bind to fibrillar insulin, we again deposited insulin fibrils on freshly cleaved mica and imaged them both topographically (Fig. 3A) and by recognition imaging using an AFM tip with an anti-BRG1 scFv immobilized, scanning from left to right (Fig. 3B) and from right to left (Fig. 3C). The Brahma-related gene 1 (BRG1) protein is a subunit of Swi/Snf. Recognition areas shown in black are observed in each directional scan, however these areas shift substantially according to the direction of the scan (as demonstrated by the yellow arrows). The shift in recognition area to the leading edge of the fibrils seen with the control but not the G5 scFv indicates that this interaction with the control scFv is an artifact of the recognition imaging process. To ensure that the lack of specific recognition patterns observed with the control tip was not due to an absence of functional antibody immobilized on the AFM tip, we replaced the mica substrate containing insulin fibrils with a glutaraldehyde aminopropyltriethoxysilane (GD-AP TES)-treated mica substrate containing deposited human Swi/Snf, a demonstrated target antigen for the anti-BRG1 scFv [7]. The anti-BRG1 coated control tip showed substantial specific recognition to its target Swi/Snf antigen as evidenced by the images in figures 3E/F.

Atomic force microscopy recognition imaging of beta-amyloid fibrils

In order to test whether the G5 scFv would also recognize amyloid fibrils formed by an unrelated protein, we studied the force interactions between the scFv and beta-amyloid, a protein implicated in the etiology of Alzheimer’s disease [9]. Beta-amyloid (1-42) fibrils were deposited on freshly cleaved mica and imaged topographically (Fig. 4A). Recognition imaging of the fibrils was performed by scanning from left to right (Fig. 4B) and from right to left (Fig. 4C). Periodicity in the recognition spots obtained with both the insulin and beta-amyloid fibrils can be observed. The average spacing between recognition spots as calculated by measuring the distances between over 100 different pairs of spots is 22 ± 7 nm and 11 ± 4 nm for insulin and beta-amyloid fibrils, respectively (Fig. 5). The periodicity of the black recognition spots was similar to those seen on insulin fibrils (Figs. 2B/C), demonstrating specific interactions.

DISCUSSION

Aggregation of physiological, monomeric proteins into amyloid fibrils has been correlated with a number of different diseases including Alzheimer’s Disease, Parkinson’s Disease, and Type

II diabetes [1]. Understanding and preventing the formation of amyloid fibrils is an important goal in developing therapeutics for many of these diseases. Here, we describe the isolation and characterization of a monoclonal scFv raised against fibrillar insulin that also targets beta-amyloid fibrils.

A novel aspect of this research was the use of mica. Mica is well suited for phage biopanning since phage do not adhere to a freshly cleaved mica surface, whereas many other proteins and protein aggregates, including amyloid fibrils, do. We could therefore image the mica surface and verify that fibrils were on the surface, as opposed to assuming a fibrillar sample when using ELISA plates for biopanning. One could also monitor the biopanning process by using amplified phage from successive rounds of biopanning. Presumably, one would see an increase in the amount of bound phage after each round as specific clones are being isolated. However, we chose to do a phage titer instead of imaging as a time-saving procedure.

A control scFv that targets BRG1, instead of insulin, was used to verify that fibrillar insulin does not nonspecifically interact with the scFv/linker/AFM tip. While several black areas (which typically represent antibody-antigen interaction) were observed (Figs. 3B/C), these areas only occurred along the leading edges of the fibrils, depending on the direction of the scan. Furthermore, no periodicity of binding was observed as seen with the G5 scFv. Therefore, the recognition areas observed with the control scFv represent an artifact arising from the topography of the fibrils. Presence of functional control anti-BRG1 scFv on the AFM tip was verified by recognition imaging with its target antigen, the BRG1 subunit of human Swi/Snf [7, 19] (Figs. 3E/F). We postulate that the non-specific recognition events observed at the leading edge of the fibrils during the scanning process is the result of the sharp change in height the AFM tip and the tethered scFv experience in going from scanning the mica surface to scanning the top surface of the fibrils. This artifactual recognition event is not observed when specific antibody antigen interactions are present as evidenced by the scans made of the fibrils with the G5 scFv coated tip. Actual recognition events between the tip and fibrils may prevent the generation of artifactual recognition events since any height changed induced fluctuations of the tethered scFv on the tip are damped by binding to the immobilized fibrils.

Since antibodies against fibrils were previously shown to target a variety of fibrils regardless of protein composition [10], we tested the specificity of G5 scFv for recognition to a different type of fibril formed from the protein beta-amyloid (Figs. 4(B/C)). The G5 scFv shows periodicity in binding to both insulin and beta-amyloid fibrils indicating that the G5 scFv recognizes a shared motif between insulin and beta-amyloid fibrils, likely the cross-beta sheet motif characteristic of amyloid fibrils [20]. Periodicity in amyloid fibril structure has been well documented due to packing of the 0.47 nm beta-sheet structures, with reported periodicity measurements for Islet Amyloid ProPeptide (IAPP) and beta-amyloid of 25 nm and 40 nm, respectively [21,22]. The measured periodicity values obtained here of 22 and 11 nm (Fig. 5) for insulin and beta-amyloid respectively, are in the same range as previously reported indicating that recognition imaging can be a valuable tool for probing amyloid structure.

This work has outlined a protocol that researchers can adopt for studying protein aggregation. Since the recognition imaging can detect periodic binding to a particular site, anti-fibrillar antibodies and recognition imaging can be used to further probe the structure of amyloid fibrils. The scFv's can also serve as potential therapeutics aimed at targeting fibrils *in vivo* since the scFv is based on a human antibody scaffold.

ACKNOWLEDGMENTS

We thank the National Institutes of Health for funding this research through the minority postdoctoral supplement award.

Support: National Institutes of Health Minority Postdoctoral Supplement

References

- [1]. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. *Biochim Biophys Acta* 2004;1739:5–25. [PubMed: 15607113]
- [2]. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. *J Neurosci Res* 2006;83:374–384. [PubMed: 16385556]
- [3]. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. *J Neurosci* 2004;24:1888–1896. [PubMed: 14985429]
- [4]. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. *Nat Neurosci* 2004;7:1181–1183. [PubMed: 15475950]
- [5]. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. *Protein Sci* 2000;9:1960–1967. [PubMed: 11106169]
- [6]. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. *Nature* 1991;352:624–628. [PubMed: 1907718]
- [7]. Marcus WD, Wang H, Lohr D, Sierks MR, Lindsay SM. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. *Biochem Biophys Res Commun* 2006;342:1123–1129. [PubMed: 16513088]
- [8]. Stroh C, Wang H, Bash R, Ashcroft B, Nelson J, Gruber H, Lohr D, Lindsay SM, Hinterdorfer P. Single-molecule recognition imaging microscopy. *Proc Natl Acad Sci U S A* 2004;101:12503–12507. [PubMed: 15314231]
- [9]. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 2001;81:741–766. [PubMed: 11274343]
- [10]. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. *Proc Natl Acad Sci U S A* 2002;99:1485–1490. [PubMed: 11818542]
- [11]. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. *Nat Biotechnol* 1999;17:568–572. [PubMed: 10385321]
- [12]. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytotoxicity. *Mol Immunol* 1999;36:433–445. [PubMed: 10449096]
- [13]. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. *Mol Ther* 2004;10:1023–1031. [PubMed: 15564134]
- [14]. Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. *Protein Eng Des Sel* 2006;19:497–502. [PubMed: 16984950]
- [15]. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. *J Mol Biol* 2007;368:1132–1144. [PubMed: 17391701]
- [16]. Wang H, Bash R, Yodh JG, Hager G, Lindsay SM, Lohr D. Using atomic force microscopy to study nucleosome remodeling on individual nucleosomal arrays in situ. *Biophys J* 2004;87:1964–1971. [PubMed: 15345572]
- [17]. Wang H, Bash R, Yodh JG, Hager GL, Lohr D, Lindsay SM. Glutaraldehyde modified mica: a new surface for atomic force microscopy of chromatin. *Biophys J* 2002;83:3619–3625. [PubMed: 12496129]
- [18]. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. *Neurobiol Dis* 2005;20:74–81. [PubMed: 16137568]
- [19]. Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. *Mol Cell* 1999;3:247–253. [PubMed: 10078207]
- [20]. Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross-beta protein. *Proc Soc Exp Biol Med* 1969;131:1373–1375. [PubMed: 5812002]

- [21]. Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid state nuclear magnetic resonance. *Biochemistry* 2002;41:15436–15450. [PubMed: 12484785]
- [22]. Stromer T, Serpell LC. Structure and morphology of the Alzheimer's amyloid fibril. *Microsc Res Tech* 2005;67:210–217. [PubMed: 16103997]

Figure 1. Protein and antibody characterization. (A) Monomeric fraction and fibrillar fraction of insulin, used to coat ELISA wells, separated on a tricine gel. (B) An scFv ELISA result using the G5 scFv in wells coated as labeled above. The control wells are coated with 2% MPBS. The results are an average of 5 replicates, with $p < 0.005$ for the fibrillar and monomeric mix values.

Figure 2.

Atomic force microscopy recognition imaging of Insulin by the G5 scFv. (A) This is a representative topographical image of insulin fibrils, with the recognition by the G5 scFv shown in black on scan (B) representing the recognition image scanned from left to right and on scan (C) representing the recognition image scanned from right to left. (D) This is a representative topographical image of monomeric/small aggregates of insulin, with the recognition scans shown in (E) and (F). The scale bars on the topographical scans are 400 nm.

Figure 3. Control recognition images. (A) This is a representative topographical image of insulin fibrils, with apparent recognition by the irrelevant anti-BRG1 scFv shown in black on scan (B) representing the recognition image scanned from left to right and on scan (C) representing the recognition image scanned from right to left. The yellow arrows point out the shifting “recognition” for a particular fibril that occurs depending on the direction of the scan. The anti-BRG1 scFv was then used for (D) topographic scans and for (E and F) recognition imaging of Swi/Snf. The scale bar is 400 nm.

Figure 4. Atomic force microscopy recognition imaging of Beta-amyloid fibrils by the G5 scFv. This representative scan shows beta-amyloid imaged (A) topographically with recognition shown as black spots and (B) scanned from left to right and (C) scanned from right to left. The scale bar is 400 nm.

Figure 5. Higher magnification images of an insulin fibril imaged (A) topographically or by (B) recognition imaging; and beta-amyloid fibrils imaged (C) topographically and by (D) recognition imaging. Periodicity is determined by the average distance between near pairs of black dots. The scale bar is 50 nm.